Erythropoiesis Stimulating Agent (ESA) use, by DOPPS country and cross-section

  N Ptnts Total N Wgtd %
DOPPS Country DOPPS Cross-section 448 510 87.4%
AusNZ D2(2002)
D3(2006) 475 518 91.0%
D3(2007) 432 480 89.7%
D4(2010) 225 254 87.7%
Belgium D2(2002) 508 537 94.8%
D3(2006) 480 499 96.3%
D3(2007) 390 411 95.3%
D4(2010) 395 410 96.0%
Canada D2(2002) 544 585 92.1%
D3(2006) 519 544 95.3%
D3(2007) 421 441 93.6%
D4(2010) 272 295 92.3%
France D2(2002) 435 508 85.8%
D3(2006) 510 549 92.9%
D3(2007) 504 543 93.1%
D4(2010) 302 342 89.2%
Germany D2(2002) 497 563 88.0%
D3(2006) 514 573 89.3%
D3(2007) 567 622 90.5%
D4(2010) 456 507 89.2%
Italy D2(2002) 504 572 87.0%
D3(2006) 460 518 88.4%
D3(2007) 472 541 86.5%
D4(2010) 374 414 90.1%
Japan D2(2002) 1,472 1,763 82.1%
D3(2006) 1,531 1,824 82.8%
D3(2007) 1,548 1,847 83.6%
D4(2010) 1,424 1,620 87.3%
Spain D2(2002) 570 605 93.9%
D3(2006) 618 662 93.7%
D3(2007) 513 551 93.6%
D4(2010) 485 543 89.6%
Sweden D2(2002) 515 545 95.1%
D3(2006) 515 537 96.2%
D3(2007) 480 509 94.6%
D4(2010) 391 427 91.3%
UK D2(2002) 527 555 95.1%
D3(2006) 407 437 93.1%
D3(2007) 326 349 94.7%
D4(2010) 318 354 90.2%
US D2(2002) 2,054 2,238 91.9%
D3(2006) 1,677 1,805 93.5%
D3(2007) 1,235 1,316 94.3%
D4(2010) 3,020 3,183 95.3%

Any ESA prescription in previous 3 months, among all patients

Please see additional methodological information in the Data Sources and Methods section.